Abiopharma

🔍 Friedl-Naderer Johanna (Executive)

Company: Dyne Therapeutics, Inc. (DYN)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Sold 894 shares of Common Stock at $13.27 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: false | shares_owned_after: 95,017.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 144 shares of Common Stock at $13.41 per share (Direct)
  Date: 2025-09-05 | Code: S | equity_swap_involved: false | shares_owned_after: 94,873.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.08 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
• F3: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
• F4: Includes 74,514 unvested RSUs.